Clinical review report. Safinamide (Onstryv) (Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "off" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD.

Clinical review report. indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "off" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD. Safinamide (Onstryv) (Valeo Pharma Inc.) :

Show other versions (2)

The objective of this report was to perform a systematic review of the beneficial and harmful effects of safinamide oral tablets, 50 mg or 100 mg, as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease in patients experien...

Full description

Saved in:
Bibliographic Details
Online Access: Full text
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2020
Edition:Version: final (with redactions).
Series:Common drug review clinical review report.
Subjects:
Parkinson Disease > drug therapy.
Alanine > therapeutic use.
Monoamine Oxidase Inhibitors > therapeutic use.
Alanine > adverse effects.
Monoamine Oxidase Inhibitors > adverse effects.
Antiparkinson Agents > therapeutic use.
Drug Therapy, Combination.
Systematic Review.

Internet

Full text

Similar Items